TWD 70.8
(0.28%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 685.92 Million TWD | 65.56% |
2022 | 414.31 Million TWD | 39.16% |
2021 | 297.71 Million TWD | -23.9% |
2020 | 391.22 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 810.1 Million TWD | 23.64% |
2024 Q1 | 655.21 Million TWD | -4.48% |
2023 Q2 | 734.5 Million TWD | 0.0% |
2023 FY | 685.92 Million TWD | 65.56% |
2023 Q4 | 685.92 Million TWD | 0.0% |
2023 Q3 | 685.92 Million TWD | -6.61% |
2023 Q1 | - TWD | -100.0% |
2022 FY | 414.31 Million TWD | 39.16% |
2022 Q4 | 414.31 Million TWD | 0.0% |
2021 FY | 297.71 Million TWD | -23.9% |
2020 FY | 391.22 Million TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Apex Biotechnology Corp. | 2.29 Billion TWD | 70.138% |
Sinphar Pharmaceutical Co.,Ltd. | 6.25 Billion TWD | 89.027% |
Panion & Bf Biotech Inc. | 3.23 Billion TWD | 78.798% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 5.17 Billion TWD | 86.737% |
GenMont Biotech Incorporation | 1.65 Billion TWD | 58.509% |
Abnova (Taiwan) Corporation | 1.35 Billion TWD | 49.406% |
Adimmune Corporation | 9.48 Billion TWD | 92.768% |
Tanvex BioPharma, Inc. | 2.76 Billion TWD | 75.178% |
Polaris Group | 9.09 Billion TWD | 92.461% |
Energenesis Biomedical CO.,LTD. | 828.57 Million TWD | 17.215% |
PELL Bio-Med Technology Co. Ltd. | 1.41 Billion TWD | 51.632% |